MedTrace Logo

Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

NCT07132801 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-08-20

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Conditions

  • NAD
  • NAD+ Levels in the Blood

Interventions

DIETARY_SUPPLEMENT

Qualia NAD⁺ version 1

Qualia NAD+ version 1 manufactured by Qualia Life Sciences

DIETARY_SUPPLEMENT

Qualia NAD⁺ version 2

Qualia NAD+ version 2 manufactured by Qualia Life Sciences

DIETARY_SUPPLEMENT

Placebo

Rice Flour

Sponsors & Collaborators

  • Qualia Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2025-11-30
Completion
2025-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07132801 on ClinicalTrials.gov